Literature DB >> 7780957

Mutational effects on the p16INK4a tumor suppressor protein.

R Yang1, A F Gombart, M Serrano, H P Koeffler.   

Abstract

Several point mutations of p16INK4a were studied by site-specific mutagenesis and functional analysis to assess the effects of these mutations on the function of the protein. These mutations were reported in several malignancies. Three deletional mutants of p16INK4a were also analyzed to reveal the relationship between p16INK4a and p15INK4b and to test the importance of the ankyrin repeats observed in both proteins. We studied the activity of these mutants using the yeast two-hybrid system and an in vitro kinase assay. Our results suggest that point mutations in the conserved ankyrin consensus affect the activity of p16INK4a. However, not all of the point mutations observed in tumors have a detectable effect on the activity. The COOH-terminal region of p16INK4a is not required for the protein to bind and to inhibit CDK4, but the deletion of the 4th ankyrin repeat abolished the activity completely.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780957

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.

Authors:  M Pinyol; L Hernández; A Martínez; F Cobo; S Hernández; S Beà; A López-Guillermo; I Nayach; A Palacín; A Nadal; P L Fernández; E Montserrat; A Cardesa; E Campo
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.

Authors:  J A Boice; R Fairman
Journal:  Protein Sci       Date:  1996-09       Impact factor: 6.725

3.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.

Authors:  A K El-Naggar; S Lai; G Clayman; J K Lee; M A Luna; H Goepfert; J G Batsakis
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

4.  Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.

Authors:  E Nishiwaki; S L Turner; S Harju; S Miyazaki; M Kashiwagi; J Koh; H Serizawa
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.

Authors:  D Parry; G Peters
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

6.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Tumor suppressor genes and related molecules in leiomyosarcoma.

Authors:  A P Dei Tos; R Maestro; C Doglioni; S Piccinin; D D Libera; M Boiocchi; C D Fletcher
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma.

Authors:  Wei-Wei Shen; Jun Wu; Li Cai; Bing-Ya Liu; Yan Gao; Guo-Qiang Chen; Guo-Hui Fu
Journal:  Neoplasia       Date:  2007-10       Impact factor: 5.715

9.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.

Authors:  D S Franklin; V L Godfrey; H Lee; G I Kovalev; R Schoonhoven; S Chen-Kiang; L Su; Y Xiong
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

10.  Simulation of different truncated p16(INK4a) forms and in silico study of interaction with Cdk4.

Authors:  Najmeh Fahham; Mohammad Hossein Ghahremani; Soroush Sardari; Behrouz Vaziri; Seyed Nasser Ostad
Journal:  Cancer Inform       Date:  2008-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.